HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation.

Abstract

The cysteinyl leukotrienes (CysLTs) are inflammatory mediators closely associated with neuronal injury after brain ischemia through the activation of their receptors, CysLT1R and CysLT2R. Here we investigated the involvement of both receptors in oxygen-glucose deprivation/recovery (OGD/R)-induced ischemic neuronal injury and the effect of the novel CysLT2R antagonist HAMI 3379 [3-({[(1S,3S)-3- carboxycyclohexyl]amino}carbonyl)-4-(3-{4-[4-(cyclo-hexyloxy)butoxy]phenyl}propoxy)benzoic acid] in comparison with the CysLT1R antagonist montelukast. In primary neurons, neither the nonselective agonist leukotriene D4 (LTD4) nor the CysLT2R agonist N-methyl-leukotriene C4 (NMLTC4) induced neuronal injury, and HAMI 3379 did not affect OGD/R-induced neuronal injury. However, in addition to OGD/R, LTD4 and NMLTC4 induced cell injury and neuronal loss in mixed cultures of cortical cells, and neuronal loss and necrosis in neuron-microglial cocultures. Moreover, they induced phagocytosis and cytokine release (interleukin-1β and tumor necrosis factor-α) from primary microglia, and conditioned medium from the treated microglia induced neuronal necrosis. HAMI 3379 inhibited all of these responses, and its effects were the same as those of CysLT2R interference by CysLT2R short hairpin RNA, indicating CysLT2R dependence. In comparison, montelukast moderately inhibited OGD/R-induced primary neuronal injury and most OGD/R- and LTD4-induced (but not NMLTC4-induced) responses in mixed cultures, cocultures, and microglia. The effects of montelukast were both dependent and independent of CysLT1Rs because interference by CysLT1R small interfering RNA had limited effects on neuronal injury in neuron-microglial cocultures and on cytokine release from microglia. Our findings indicated that HAMI 3379 effectively blocked CysLT2R-mediated microglial activation, thereby indirectly attenuating ischemic neuronal injury. Therefore, CysLT2R antagonists may represent a new type of therapeutic agent in the treatment of ischemic stroke.

• Authors: Xia-Yan Zhang, Xiao-Rong Wang, Dong-Min Xu, Shu-Ying Yu, Qiao-Juan Shi, Li-Hui Zhang, Lu Chen, San-Hua Fang, Yun-Bi Lu, Wei-Ping Zhang, Er-Qing Wei
• Journal: The Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 346 Issue 2 Pg. 328-41 (Aug 2013) ISSN: 1521-0103 [Electronic] United States
• PMID: 23750020 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-(cyclohexyloxy)butoxy)phenyl)propoxy)benzoic acid
• Acetates
• Cyclohexanecarboxylic Acids
• Cyclopropanes
• Cytokines
• Leukotriene Antagonists
• Phthalic Acids
• Quinolines
• Receptors, Leukotriene
• Sulfides
• cysteinyl leukotriene receptor 2
• Glucose
• montelukast
• Oxygen

Topics

• Acetates (pharmacology)
• Animals
• Animals, Newborn
• Astrocytes (drug effects, metabolism, pathology)
• Brain Ischemia (metabolism, pathology)
• Cell Hypoxia
• Cells, Cultured
• Cerebral Cortex (cytology)
• Coculture Techniques
• Cyclohexanecarboxylic Acids (pharmacology)
• Cyclopropanes
• Cytokines (metabolism)
• Female
• Glucose (metabolism)
• Leukotriene Antagonists (pharmacology)
• Male
• Microglia (drug effects, metabolism, pathology)
• Necrosis
• Neurons (drug effects, metabolism, pathology)
• Oxygen (metabolism)
• Phagocytosis
• Phthalic Acids (pharmacology)
• Primary Cell Culture
• Quinolines (pharmacology)
• Rats
• Rats, Sprague-Dawley
• Receptors, Leukotriene (agonists, metabolism)
• Sulfides